John Reynolds

My first interview with Bernard Looney took place in his glass-fronted office in BP, with a press officer and a Trinidadian female assistant sitting in as well. His accent was more mid-Atlantic than Kerry, and he looked set for greatness. Where did it go wrong?

Dublin-headquartered Carbon Collect has a prototype to suck carbon out of the atmosphere, partners in Arizona and is short-listed for US government funding. Its Irish co-founder Pól Ó Móráin is seeking backing to scale up in 2026.

Having just closed a €5.35m seed funding round, Dublin-based privacy tech start-up Oblivious has big plans. Co-founder Robert Pisarczyk talks about the company’s mission, the rise of privacy tech, and how the funding will assist growth in key markets.

AI such as GPT-4 will enable cheaper, more ambitious movie special effects, says Framestore’s William Sargent. He sees this as another step in the evolving world of knowledge-based jobs.

Eddie McGillycuddy's Glencar has honed its construction skills on warehouse and industrial facilities for the likes of Ocado. However, it has since diversified into student accommodation and offices. It now expects revenues to hit between £550m and £600m this year.

Europe’s wind sector is in peril, and it can’t decarbonise power unless it rediscovers its confidence and unites to build the supergrid, says Supernode founder Eddie O’Connor.

Analysis of more than €1.6 billion of HSE spending shows just one recruitment firm received €478 million in less than four years and ten others shared over €1 billion – for an unknown number of staff.

Finbourne, led by Irish former bankers Thomas McHugh and Dermot Shortt, has just secured £30m of debt funding to support its expansion. What next for the fast-growing financial technology business?

In a previously unpublished interview, vet to the stars Noel Fitzpatrick revealed what drives him – and hinted at why a buyout of part of his business left him in tears.

Athlone native Jack O’Meara and his South African business partner Quin Wills’ Oxford-based biotech firm has raised $30m for its mission to cure liver disease. O’Meara talks about his company’s journey, mission, and potential.